Atrial fibrillation (AF) is the most prevalent sustained cardiac arrhythmia. AF increases stroke risk and cardiovascular mortality. Atrial fibrillation was managed with antiarrhythmic drugs with limited efficacy. Recently, catheter ablation is evolving with technological advances. Pulsed field ablation (PFA) is a revolutionary technique which has gained importance in interventional electrophysiology because of its safety and efficacy. PFA is a novel non-thermal ablative modality with considerable safety and efficacy, for catheter ablation of atrial fibrillation. Several studies have demonstrated that progression of atrial fibrillation can be prevented by early ablation. The patient no longer requires to fail antiarrhythmic drugs before receiving ablation. In the European RealWorld Outcomes with Pulsed Field Ablation registry, freedom from atrial fibrillation/atrial tachycardia recurrence after 1 year was similar in patients with prior failed antiarrhythmic drug therapy compared to patients undergoing pulsed field ablation as the first-line treatment.
